| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Abel De La Rosa is Director at DWTX. Abel De La Rosa's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $4K at current prices.
Net of sales, the DWTX filings show accumulation of 4,000 shares.
Abel De La Rosa has 8 Form 4 filings on record from June 2021 to June 2026, all as Director at Dogwood Therapeutics (DWTX), 2021–2026.
The 9 reported transactions were 8 option or other derivative awards and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $24K and no sales.
The only open-market purchase was 4,000 shares of DWTX at an average $5.90 on January 7, 2022, about $24K. Twelve months later DWTX was down 95%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 7, 2022 | DWTX Dogwood Therapeutics, Inc. | Director | Buy | 4,000 | $5.90 | $23,584.00 | New | -20.1% | -95.3% |